New drug combo before surgery for stage IV stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs (immunotherapy plus a targeted pill plus chemo) versus a standard combo (immunotherapy plus chemo) before surgery, for people with stage IV stomach cancer. The goal is to see if this approach can shrink the cancer enough to make it removable, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage IV stomach cancer (or cancer where the stomach meets the food pipe) that has not been treated before.
- You are generally well enough to be up and about (ECOG score 0-1) and can have major surgery.
- Your cancer has spread to only a limited number of places, like nearby lymph nodes, liver (up to 5 spots), or the lining of the belly (peritoneum) – but not to lungs, brain, or bones.
- Your major organs (blood cells, liver, kidneys, and clotting) are working well enough, based on blood tests.
- You have not had other treatments like chemotherapy, radiation, or immunotherapy before joining this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.